arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Structure Therapeutics Inc.

GPCR

$53.18 ▲ +0.50 (+0.95%) at close

5 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Structure Therapeutics Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $9.4B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -11.7% ↗

FCF / Share $-1.27 ↘

Trailing P/E —

Price / Book 7.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-141.20M

↓ -15.2% —

FCF / Share Free cash flow per share

$-1.27

↓ -70.3% —

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	-2.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	3.7% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	85.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-15.2% Weak ↑ Weak Improving Year-over-year change in net income	-36.7% Weak Weak Year-over-year change in net income	-74.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-70.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	-0.8% Weak Weak Year-over-year change in free cash flow	84.7% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	-0.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	1.60x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-11.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	45.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-11.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-53.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-9.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-14.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-19.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-232%)	44.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+197%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-799.62M	$-169.51M	$-129.79M	$-26.09M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.80	$-0.78	$-0.81	$-5.51	—
Free Cash Flow per Share (USD)	$-1.27	$-0.75	$-0.74	$-4.83	—
Book Value per Share (USD)	$7.14	$5.03	$3.25	$-10.94	—
Tangible Book Value per Share (USD)	$7.14	$5.03	$3.25	$-10.94	—
Basic Weighted Avg Shares (shares)	177.60M	157.92M	110.20M	9.58M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$1.51B	$855.19M	$448.87M	$80.08M	—
Total Equity (USD)	$1.52B	$864.84M	$452.97M	$-115.14M	$-64.73M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Depreciation Expense (USD)	$1.33M	$992.00K	$295.00K	$277.00K	—
Net Income, GAAP (USD)	$-141.20M	$-122.53M	$-89.62M	$-51.32M	—
Operating Cash Flow (USD)	$-222.20M	$-116.64M	$-79.49M	$-46.12M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Structure Therapeutics Inc.

Analytical Summary

5-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare GPCR with peers